Dr. Harold Burstein, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Brigham And Womens Hospital|dana-farber Cancer Institute|harvard Medical School|massachusetts General Hospital

  Fellowship Hospital

• Dana-farber Cancer Institute|massachusetts General Hospital

  Residency Hospital, 1996

• Massachusetts General Hospital

  Internship Hospital, 1995

• Harvard Medical School

  Medical School, 1994

• Metastatic Breast Cancer, Version 1.2012 Featured Updates to the NCCN Guidelines, 2012-07-01

• Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance), 2016-10-04

• Breast Cancer, Version 3.2013 Featured Updates to the NCCN Guidelines, 2014-04-03

• Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium, 2020-04-24

• Radiation therapy for ductal carcinomain situ: A decision analysis, 2011-06-30

• Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics, 2012-09-23

• Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era, 2013-01-23

• Chemotherapy-Related Amenorrhea after Adjuvant Paclitaxel-Trastuzumab (APT Trial), 2015-05-16

• Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score, 2017-12-15

• Clinicopathological Features Among Patients With Advanced Human Epidermal Growth Factor-2-Positive Breast Cancer With Prolonged Clinical Benefit to First-Line Trastuzumab-Based Therapy: A Retrospective Cohort Study, 2014-05-24

• The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer, 2023-03-22

• CONTRARY EFFECTS OF THE RTK INHIBITOR VANDETANIB ON CONSTITUTIVE AND FLOW-STIMULATED NITRIC OXIDE ELABORATION IN HUMANS, 2011-04-11

• Adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression: patient-reported outcomes in the TEXT and SOFT randomised trials, 2015-06-16

• Cardiac Outcomes of Patients on Adjuvant Weekly Paclitaxel and Trastuzumab for Node Negative, HER2 Positive Breast Cancer, 2017-06-04

• Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT), 2022-11-30